The role of adjuvant immunomodulatory agents for treatment of severe influenza

Antiviral Research

Volumn 150, Issue , 2018, Pages 202-216

  Hui, David S ^a   Lee, Nelson ^a,b   Chan, Paul K ^a   Beigel, John H ^c  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF ALBERTA   (Canada)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Adjunctive therapies; Immunomodulatory agents; Influenza

Indexed keywords

ACETYLCYSTEINE; ANTIPYRETIC AGENT; ANTISERUM; CHLOROQUINE; CLARITHROMYCIN; COMPLEMENT COMPONENT C5A RECEPTOR ANTAGONIST; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; MACROLIDE; MYCOPHENOLIC ACID; NAPROXEN; NITAZOXANIDE; OSELTAMIVIR; PAMIDRONIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; POLYMYXIN B; RAPAMYCIN; RECOMBINANT INTERFERON; ANTIVIRUS AGENT; IMMUNOLOGIC FACTOR; IMMUNOLOGICAL ADJUVANT;

ADJUVANT THERAPY; ANTIVIRAL ACTIVITY; CELL THERAPY; CORTICOSTEROID THERAPY; HERBAL MEDICINE; HUMAN; IMMOBILIZED CELL; IMMUNOMODULATION; IMMUNOTHERAPY; INFLUENZA; MESENCHYMAL STROMA CELL; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW; SYSTEMIC THERAPY; TREATMENT OUTCOME; ANIMAL; COMBINATION DRUG THERAPY; DRUG EFFECT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEVERITY OF ILLNESS INDEX; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; IMMUNOTHERAPY; INFLUENZA, HUMAN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 85044290633     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2018.01.002     Document Type: Review

References (158)

1. Adisasmito, W., Chan, P.K., Lee, N., Oner, A.F., Gasimov, V., Zaman, M., Bamgboye, E., Dogan, N., Starzyk, K., Dreyer, N.A., Toovey, S., Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry. J. Infect. Dis. 202 (2010), 1154–1160.
2. Agrati, C., Gioia, C., Lalle, E., Cimini, E., Castilletti, C., Armignacco, O., Lauria, F.N., Ferraro, F., Antonini, M., Ippolito, G., Capobianchi, M.R., Martini, F., Association of profoundly impaired immune competence in H1N1v-infected patients with a severe or fatal clinical course. J. Infect. Dis. 202 (2010), 681–689.
3. Aldridge, J.R. Jr., Moseley, C.E., Boltz, D.A., Negovetich, N.J., Reynolds, C., Franks, J., Brown, S.A., Doherty, P.C., Webster, R.G., Thomas, P.G., TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. Proc Natl Acad Sci U. S. A. 106 (2009), 5306–5311.
4. Allen, S.C., Mamotte, C.D., Pleiotropic and adverse effects of statins-do epigenetics play a role?. J. Pharmacol. Exp. Ther. 362 (2017), 319–326.
5. Alsuwaidi, A.R., George, J.A., Almarzooqi, S., Hartwig, S.M., Varga, S.M., Souid, A.K., Sirolimus alters lung pathology and viral load following influenza A virus infection. Respir. Res., 18, 2017, 136.
6. Arimori, Y., Nakamura, R., Yamada, H., Shibata, K., Maeda, N., Kase, T., Yoshikai, Y., Type I interferon limits influenza virus-induced acute lung injury by regulation of excessive inflammation in mice. Antivir. Res. 99 (2013), 230–237.
7. Bauer, C.M., Zavitz, C.C., Botelho, F.M., Lambert, K.N., Brown, E.G., Mossman, K.L., Taylor, J.D., Stämpfli, M.R., Treating viral exacerbations of chronic obstructive pulmonary disease: insights from a mouse model of cigarette smoke and H1N1 influenza infection. PLoS One, 5, 2010, e13251.
8. Bautista, E., Chotpitayasunondh, T., Gao, Z.C., Harper, S.A., Hayden, F.G., Hui, D.S., Kettner, J.D., Kumar, A., Lim, M., Nicholson, K.G., Penn, C., Shaw, M., Shindo, N., Uyeki, T.M., Clinical aspects of pandemic influenza a (H1N1) 2009. N. Engl. J. Med. 362 (2010), 1708–1719.
9. Behring, E., Kitasato, S., Ueber das Zustandekommen der Diphtherie-Immunitat und der Tetanus-Immunitat bei Thieren. Dlsch. Med. Wochenschr, 16, 1890, 1113.
10. Beigel, J.H., Tebas, P., Elie-Turenne, M.C., Bajwa, E., Bell, T.E., Cairns, C.B., Shoham, S., Deville, J.G., Feucht, E., Feinberg, J., Luke, T., Raviprakash, K., Danko, J., O'Neil, D., Metcalf, J.A., King, K., Burgess, T.H., Aga, E., Lane, H.C., Hughes, M.D., Davey, R.T., IRC002 study team. Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study. Lancet Respir Med. 5 (2017), 500–511.
11. Belardo, G., Cenciarelli, O., La Frazia, S., Rossignol, J.F., Santoro, M.G., Synergistic effect of nitazoxanide with neuraminidase inhibitors against influenza A viruses in vitro. Antimicrob. Agents Chemother. 59 (2015), 1061–1069.
12. Belser, J.A., Szretter, K.J., Katz, J.M., Tumpey, T.M., Simvastatin and oseltamivir combination therapy does not improve the effectiveness of oseltamivir alone following highly pathogenic avian H5N1 influenza virus infection in mice. Virology 439 (2013), 42–46.
13. Binh, N.G., Manabe, T., Co, D.X., Tuan, N.D., Thach, P.T., Kudo, K., Polymyxin-B-immobilized-fiber column hemoperfusion with oseltamivir treatment for ARDS due to influenza H1N1/09. Respirol Case Rep 3 (2015), 57–60.
14. Bosmann, M., Ward, P.A., Protein-based therapies for acute lung injury: targeting neutrophil extracellular traps. Expert Opin. Ther. Targets 18 (2014), 703–714.
15. Bradley-Stewart, A., Jolly, L., Adamson, W., Gunson, R., Frew-Gillespie, C., Templeton, K., Aitken, C., Carman, W., Cameron, S., McSharry, C., Cytokine responses in patients with mild or severe influenza A(H1N1)pdm09. J. Clin. Virol. 58 (2013), 100–107.
16. Brassard, P., Wu, J.W., Ernst, P., Dell'Aniello, S., Smiechowski, B., Suissa, S., The effect of statins on influenza-like illness morbidity and mortality. Pharmacoepidemiol. Drug Saf. 26 (2017), 63–70.
17. Brett, S.J., Myles, P., Lim, W.S., Enstone, J.E., Bannister, B., Semple, M.G., Read, R.C., Taylor, B.L., McMenamin, J., Nicholson, K.G., Nguyen-Van-Tam, J.S., Openshaw, P.J., Influenza clinical information Network (FLU-CIN). Pre-admission statin use and in-hospital severity of 2009 pandemic influenza A(H1N1) disease. PLoS One, 6, 2011, e18120.
18. Brun-Buisson, C., Richard, J.C., Mercat, A., Thiébaut, A.C., Brochard, L., REVA-SRLF A/H1N1v 2009 registry group. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 183 (2011), 1200–1206.
19. Budd, A., Alleva, L., Alsharifi, M., Koskinen, A., Smythe, V., Müllbacher, A., Wood, J., Clark, I., Increased survival after gemfibrozil treatment of severe mouse influenza. Antimicrob. Agents Chemother. 51 (2007), 2965–2968.
20. Calkin, A.C., Cooper, M.E., Jandeleit-Dahm, K.A., Allen, T.J., Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation. Diabetologia 49 (2006), 766–774.
21. Cao, B., Gao, H., Zhou, B., Deng, X., Hu, C., Deng, C., Lu, H., Li, Y., Gan, J., Liu, J., Li, H., Zhang, Y., Yang, Y., Fang, Q., Shen, Y., Gu, Q., Zhou, X., Zhao, W., Pu, Z., Chen, L., Sun, B., Liu, X., Hamilton, C.D., Li, L., Adjuvant corticosteroid treatment in adults with influenza a (H7N9) viral pneumonia. Crit. Care Med. 44 (2016), e318–328.
22. Carey, M.A., Bradbury, J.A., Rebolloso, Y.D., Graves, J.P., Zeldin, D.C., Germolec, D.R., Pharmacologic inhibition of COX-1 and COX-2 in influenza A viral infection in mice. PLoS One, 5, 2010, e11610.
23. Carter, M.J., A rationale for using steroids in the treatment of severe cases of A/H5N1 avian influenza. J. Med. Microbiol. 56 (2007), 875–883.
24. Chan, J.F., Chan, K.H., Kao, R.Y., To, K.K., Zheng, B.J., Li, C.P., Li, P.T., Dai, J., Mok, F.K., Chen, H., Hayden, F.G., Yuen, K.Y., Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J. Infect. 67 (2013), 606–616.
25. Chan, J.F., Yao, Y., Yeung, M.L., Deng, W., Bao, L., Jia, L., Li, F., Xiao, C., Gao, H., Yu, P., Cai, J.P., Chu, H., Zhou, J., Chen, H., Qin, C., Yuen, K.Y., Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J. Infect. Dis. 212 (2015), 1904–1913.
26. Chan, M.C., Kuok, D.I., Leung, C.Y., Hui, K.P., Valkenburg, S.A., Lau, E.H., Nicholls, J.M., Fang, X., Guan, Y., Lee, J.W., Chan, R.W., Webster, R.G., Matthay, M.A., Peiris, J.S., Human mesenchymal stromal cells reduce influenza A H5N1-associated acute lung injury in vitro and in vivo. Proc Natl Acad Sci U S A 113 (2016), 3621–3626.
27. Chan, P.K., Outbreak of avian influenza A(H5N1) virus infection in Hong Kong in 1997. Clin. Infect. Dis. 34:Suppl. 2 (2002), S58–S64.
28. Chen, H., Yuan, H., Gao, R., Zhang, J., Wang, D., Xiong, Y., Fan, G., Yang, F., Li, X., Zhou, J., Zou, S., Yang, L., Chen, T., Dong, L., Bo, H., Zhao, X., Zhang, Y., Lan, Y., Bai, T., Dong, J., Li, Q., Wang, S., Zhang, Y., Li, H., Gong, T., Shi, Y., Ni, X., Li, J., Zhou, J., Fan, J., Wu, J., Zhou, X., Hu, M., Wan, J., Yang, W., Li, D., Wu, G., Feng, Z., Gao, G.F., Wang, Y., Jin, Q., Liu, M., Shu, Y., Clinical and epidemiological characteristics of a fatal case of avian influenza A H10N8 virus infection: a descriptive study. Lancet 383 (2014), 714–721.
29. Chi, Y., Zhu, Y., Wen, T., Cui, L., Ge, Y., Jiao, Y., Wu, T., Ge, A., Ji, H., Xu, K., Bao, C., Zhu, Z., Qi, X., Wu, B., Shi, Z., Tang, F., Xing, Z., Zhou, M., Cytokine and chemokine levels in patients infected with the novel avian influenza A (H7N9) virus in China. J. Infect. Dis. 208 (2013), 1962–1967.
30. Cho, J., Yi, H., Jang, E.Y., Lee, M.S., Lee, J.Y., Kang, C., Lee, C.H., Kim, K., Mycophenolic mofetil, an alternative antiviral and immunomodulator for the highly pathogenic avian influenza H5N1 virus infection. Biochem. Biophys. Res. Commun. 494 (2017), 298–304.
31. Crotta, S., Davidson, S., Mahlakoiv, T., Desmet, C.J., Buckwalter, M.R., Albert, M.L., Staeheli, P., Wack, A., Type I and type III interferons drive redundant amplification loops to induce a transcriptional signature in influenza-infected airway epithelia. PLoS Pathog., 9, 2013, e1003773.
32. Darwish, I., Banner, D., Mubareka, S., Kim, H., Besla, R., Kelvin, D.J., Kain, K.C., Liles, W.C., Mesenchymal stromal (stem) cell therapy fails to improve outcomes in experimental severe influenza. PLoS One, 8, 2013, e71761.
33. de Jong, M.D., Simmons, C.P., Thanh, T.T., Hien, V.M., Smith, G.J., Chau, T.N., Hoang, D.M., Chau, N.V., Khanh, T.H., Dong, V.C., Qui, P.T., Cam, B.V., Ha do, Q., Guan, Y., Peiris, J.S., Chinh, N.T., Hien, T.T., Farrar, J., Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med. 12 (2006), 1203–1207.
34. Delaney, J.W., Pinto, R., Long, J., Lamontagne, F., Adhikari, N.K., Kumar, A., Marshall, J.C., Cook, D.J., Jouvet, P., Ferguson, N.D., Griesdale, D., Burry, L.D., Burns, K.E., Hutchison, J., Mehta, S., Menon, K., Fowler, R.A., Canadian critical care trials group H1N1 collaborative. The influence of corticosteroid treatment on the outcome of influenza A(H1N1pdm09)-related critical illness. Crit. Care, 20, 2016, 75.
35. Di Trani, L., Savarino, A., Campitelli, L., Norelli, S., Puzelli, S., D'Ostilio, D., Vignolo, E., Donatelli, I., Cassone, A., Different pH requirements are associated with divergent inhibitory effects of chloroquine on human and avian influenza A viruses. Virol. J., 4, 2007, 39.
36. Diaz, E., Martin-Loeches, I., Canadell, L., Vidaur, L., Suarez, D., Socias, L., Estella, A., Gil Rueda, B., Guerrero, J.E., Valverdú-Vidal, M., Vergara, J.C., López-Pueyo, M.J., Magret, M., Recio, T., López, D., Rello, J., Rodriguez, A., H1N1 Semicyuc-Ciberes-REIPI working group (GETGAG). Corticosteroid therapy in patients with primary viral pneumonia due to pandemic (H1N1) 2009 influenza. J. Infect. 64 (2012), 311–318.
37. Dinglas, V.D., Hopkins, R.O., Wozniak, A.W., Hough, C.L., Morris, P.E., Jackson, J.C., Mendez-Tellez, P.A., Bienvenu, O.J., Ely, E.W., Colantuoni, E., Needham, D.M., One-year outcomes of rosuvastatin versus placebo in sepsis-associated acute respiratory distress syndrome: prospective follow-up of SAILS randomised trial. Thorax 71 (2016), 401–410.
38. Duan, Z.P., Jia, Z.H., Zhang, J., Liu, S., Chen, Y., Liang, L.C., Zhang, C.Q., Zhang, Z., Sun, Y., Zhang, S.Q., Wang, Y.Y., Wu, Y.L., Natural herbal medicine Lianhuaqingwen capsule anti-influenza A (H1N1) trial: a randomized, double blind, positive controlled clinical trial. Chin Med J (Engl) 124 (2011), 2925–2933.
39. Duggal, A., Pinto, R., Rubenfeld, G., Fowler, R.A., Global Variability in Reported Mortality for Critical Illness during the 2009-10 Influenza A(H1N1) Pandemic: a Systematic Review and Meta-Regression to Guide Reporting of Outcomes during Disease Outbreaks. PLoS One, 11, 2016, e0155044.
40. Durbin, R.K., Kotenko, S.V., Durbin, J.E., Interferon induction and function at the mucosal surface. Immunol. Rev. 255 (2013), 25–39.
41. Eyers, S., Weatherall, M., Shirtcliffe, P., Perrin, K., Beasley, R., The effect on mortality of antipyretics in the treatment of influenza infection: systematic review and meta-analysis. J. Roy. Soc. Med. 103 (2010), 403–411.
42. Fedson, D.S., Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: why they are needed and how they might work. Influenza. Respi Viruses 3 (2009), 129–142.
43. Gao, R., Cao, B., Hu, Y., Feng, Z., Wang, D., Hu, W., Chen, J., Jie, Z., Qiu, H., Xu, K., Xu, X., Lu, H., Zhu, W., Gao, Z., Xiang, N., Shen, Y., He, Z., Gu, Y., Zhang, Z., Yang, Y., Zhao, X., Zhou, L., Li, X., Zou, S., Zhang, Y., Li, X., Yang, L., Guo, J., Dong, J., Li, Q., Dong, L., Zhu, Y., Bai, T., Wang, S., Hao, P., Yang, W., Zhang, Y., Han, J., Yu, H., Li, D., Gao, G.F., Wu, G., Wang, Y., Yuan, Z., Shu, Y., Human infection with a novel avian-origin influenza A (H7N9) virus. N. Engl. J. Med. 368 (2013), 1888–1897.
44. Garozzo, A., Tempera, G., Ungheri, D., Timpanaro, R., Castro, A., N-acetylcysteine synergizes with oseltamivir in protecting mice from lethal influenza infection. Int. J. Immunopathol. Pharmacol. 20 (2007), 349–354.
45. Geiler, J., Michaelis, M., Naczk, P., Leutz, A., Langer, K., Doerr, H.W., Cinatl, J. Jr., N-acetyl-l-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus. Biochem. Pharmacol. 79 (2010), 413–420.
46. Gelfand, E.W., Intravenous immune globulin in autoimmune and inflammatory diseases. N. Engl. J. Med. 367 (2012), 2015–2025.
47. Glück, B., Schmidtke, M., Walther, M., Meerbach, A., Wutzler, P., Simvastatin treatment showed no prophylactic effect in influenza virus-infected mice. J. Med. Virol. 85 (2013), 1978–1982.
48. Guihot, A., Luyt, C.E., Parrot, A., Rousset, D., Cavaillon, J.M., Boutolleau, D., Fitting, C., Pajanirassa, P., Mallet, A., Fartoukh, M., Agut, H., Musset, L., Zoorob, R., Kirilovksy, A., Combadière, B., van der Werf, S., Autran, B., Carcelain, G., FluBAL Study Group. Low titers of serum antibodies inhibiting hemagglutination predict fatal fulminant influenza A(H1N1) 2009 infection. Am. J. Respir. Crit. Care Med., 189, 2014 1240–1209.
49. Guo, X.J., Thomas, P.G., New fronts emerge in the influenza cytokine storm. Semin. Immunopathol. 39 (2017), 541–550.
50. Haasbach, E., Droebner, K., Vogel, A.B., Planz, O., Low-dose interferon Type I treatment is effective against H5N1 and swine-origin H1N1 influenza A viruses in vitro and in vivo. J. Interferon Cytokine Res. 31 (2011), 515–525.
51. Haffizulla, J., Hartman, A., Hoppers, M., Resnick, H., Samudrala, S., Ginocchio, C., Bardin, M., Rossignol, J.F., US nitazoxanide influenza clinical study group. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial. Lancet Infect. Dis. 14 (2014), 609–618.
52. Han, K., Ma, H., An, X., Su, Y., Chen, J., Lian, Z., Zhao, J., Zhu, B.P., Fontaine, R.E., Feng, Z., Zeng, G., Early use of glucocorticoids was a risk factor for critical disease and death from pH1N1 infection. Clin. Infect. Dis. 53 (2011), 326–333.
53. Hohenadl, C., Wodal, W., Kerschbaum, A., Fritz, R., Howard, M.K., Farcet, M.R., Portsmouth, D., McVey, J.K., Baker, D.A., Ehrlich, H.J., Barrett, P.N., Kreil, T.R., Hyperimmune intravenous immunoglobulin containing high titers of pandemic H1N1 hemagglutinin and neuraminidase antibodies provides dose-dependent protection against lethal virus challenge in SCID mice. Virol. J., 11, 2014, 70.
54. Hong, D.K., Tremoulet, A.H., Burns, J.C., Lewis, D.B., Cross-reactive neutralizing antibody against pandemic 2009 H1N1 influenza A virus in intravenous immunoglobulin preparations. Pediatr. Infect. Dis. J. 30 (2011), 67–69.
55. Hsu, A.C., Parsons, K., Barr, I., Lowther, S., Middleton, D., Hansbro, P.M., Wark, P.A., Critical role of constitutive type I interferon response in bronchial epithelial cell to influenza infection. PLoS One, 7, 2012, e32947.
56. Hsu, J.C., Ross-Degnan, D., Wagner, A.K., Zhang, F., Lu, C.Y., How did multiple FDA actions affect the utilization and reimbursed costs of thiazolidinediones in US medicaid?. Clin. Ther. 37 (2015), 1420–1432.
57. Hui, D.S., Lee, N., Chan, P.K., Adjunctive therapies and immunomodulatory agents in the management of severe influenza. Antivir. Res. 98 (2013), 410–416.
58. Hung, I.F., To, K.K., Lee, C.K., Lee, K.L., Chan, K., Yan, W.W., Liu, R., Watt, C.L., Chan, W.M., Lai, K.Y., Koo, C.K., Buckley, T., Chow, F.L., Wong, K.K., Chan, H.S., Ching, C.K., Tang, B.S., Lau, C.C., Li, I.W., Liu, S.H., Chan, K.H., Lin, C.K., Yuen, K.Y., Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin. Infect. Dis. 52 (2011), 510–519.
59. Hung, I.F., To, K.K., Lee, C.K., Lee, K.L., Yan, W.W., Chan, K., Chan, W.M., Ngai, C.W., Law, K.I., Chow, F.L., Liu, R., Lai, K.Y., Lau, C.C., Liu, S.H., Chan, K.H., Lin, C.K., Yuen, K.Y., Hyperimmune intravenous immunoglobulin treatment: a multicentre double-blind randomized controlled trial for patients with severe A(H1N1)pdm09 infection. Chest 144 (2013), 464–473.
60. Hung, I.F., To, K.K., Chan, J.F., Cheng, V.C., Liu, K.S., Tam, A., Chan, T.C., Zhang, A.J., Li, P., Wong, T.L., Zhang, R., Cheung, M.K., Leung, W., Lau, J.Y., Fok, M., Chen, H., Chan, K.H., Yuen, K.Y., Efficacy of clarithromycin-naproxen-oseltamivir combination in the treatment of patients hospitalized for influenza A(H3N2) infection: an open-label randomized, controlled, phase IIb/III trial. Chest 151 (2017), 1069–1080.
61. Ilyushina, N.A., Donnelly, R.P., In vitro anti-influenza A activity of interferon (IFN)-λ1 combined with IFN-β or oseltamivir carboxylate. Antivir. Res. 111 (2014), 112–120.
62. Ishii, H., Komiya, K., Yamagata, E., Yatera, K., Chojin, Y., Yamamoto, H., Mukae, H., Kadota, J., Clarithromycin has limited effects in non-elderly, non-severe patients with seasonal influenza virus A infection. J. Infect. 64 (2012), 343–345.
63. Jefferies, S., Braithwaite, I., Walker, S., Weatherall, M., Jennings, L., Luck, M., Barrett, K., Siebers, R., Blackmore, T., Beasley, R., Perrin, K., Pi study group. Randomized controlled trial of the effect of regular paracetamol on influenza infection. Respirology 21 (2016), 370–377.
64. Jain, M.K., Ridker, P.M., Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat. Rev. Drug Discov. 4 (2005), 977–987.
65. Jiang, H., Wu, P., Uyeki, T.M., He, J., Deng, Z., Xu, W., Lv, Q., Zhang, J., Wu, Y., Tsang, T.K., Kang, M., Zheng, J., Wang, L., Yang, B., Qin, Y., Feng, L., Fang, V.J., Gao, G.F., Leung, G.M., Yu, H., Cowling, B.J., Preliminary epidemiologic assessment of human infections with highly pathogenic avian influenza A(H5N6) virus, China. Clin. Infect. Dis. 65 (2017), 383–388.
66. Jiang, L., Deng, L., Wu, T., Chinese medicinal herbs for influenza. Cochrane Database Syst Rev., 3, 2013 CD004559.
67. Kakeya, H., Seki, M., Izumikawa, K., Kosai, K., Morinaga, Y., Kurihara, S., Nakamura, S., Imamura, Y., Miyazaki, T., Tsukamoto, M., Yanagihara, K., Tashiro, T., Kohno, S., Efficacy of combination therapy with oseltamivir phosphate and azithromycin for influenza: a multicenter, open-label, randomized study. PLoS One, 9, 2014, e91293.
68. Kanoh, S., Rubin, B.K., Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin. Microbiol. Rev. 23 (2010), 590–615.
69. Kim, S.H., Hong, S.B., Yun, S.C., Choi, W.I., Ahn, J.J., Lee, Y.J., Lee, H.B., Lim, C.M., Koh, Y., Korean Society of Critical Care Medicine H1N1 Collaborative. Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores. Am. J. Respir. Crit. Care Med. 183 (2011), 1207–1214.
70. Kubota-Koketsu, R., Yunoki, M., Okuno, Y., Ikuta, K., Significant neutralizing activities against H2N2 influenza A viruses in human intravenous immunoglobulin lots manufactured from 1993 to 2010. Biologics 6 (2012), 245–247.
71. Kudo, K., Takasaki, J., Manabe, T., Uryu, H., Yamada, R., Kuroda, E., Kobayashi, N., Matsushita, T., Systemic corticosteroids and early administration of antiviral agents for pneumonia with acute wheezing due to influenza A(H1N1)pdm09 in Japan. PLoS One, 7, 2012, e32280.
72. Kudo, K., Binh, N.G., Manabe, T., Co, D.X., Tuan, N.D., Izumi, S., Takasaki, J., Minh, D.H., Thuy, P.T., Van, V.T., Hanh, T.T., Chau, N.Q., Clinical preparedness for severe pneumonia with highly pathogenic avian influenza A (H5N1): experiences with cases in Vietnam. Respir Investig 50 (2012), 140–150.
73. Kwong, J.C., Li, P., Redelmeier, D.A., Influenza morbidity and mortality in elderly patients receiving statins: a cohort study. PLoS One, 4, 2009, e8087.
74. Lai, K.Y., Ng, W.Y., Osburga Chan, P.K., Wong, K.F., Cheng, F., High-dose N-acetylcysteine therapy for novel H1N1 influenza pneumonia. Ann. Intern. Med. 152 (2010), 687–688.
75. Laidler, M.R., Thomas, A., Baumbach, J., Kirley, P.D., Meek, J., Aragon, D., Morin, C., Ryan, P.A., Schaffner, W., Zansky, S.M., Chaves, S.S., Statin treatment and mortality: propensity score-matched analyses of 2007-2008 and 2009-2010 laboratory-confirmed influenza hospitalizations. Open Forum Infect. Dis., 2(1), 2015 ofv028.
76. Lat, A., Bhadelia, N., Miko, B., Furuya, E.Y., Thompson, G.R. 3rd, Invasive aspergillosis after pandemic (H1N1) 2009. Emerg. Infect. Dis. 16 (2010), 971–973.
77. Lee, N., Chan, P.K., Hui, D.S., Rainer, T.H., Wong, E., Choi, K.W., Lui, G.C., Wong, B.C., Wong, R.Y., Lam, W.Y., Chu, I.M., Lai, R.W., Cockram, C.S., Sung, J.J., Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J. Infect. Dis. 200 (2009), 492–500.
78. Lee, N., Choi, K.W., Chan, P.K., Hui, D.S., Lui, G.C., Wong, B.C., Wong, R.Y., Sin, W.Y., Hui, W.M., Ngai, K.L., Cockram, C.S., Lai, R.W., Sung, J.J., Outcomes of adults hospitalized with severe influenza. Thorax 65 (2010), 510–515.
79. Lee, N., Chan, P.K., Wong, C.K., Wong, K.T., Choi, K.W., Joynt, G.M., Lam, P., Chan, M.C., Wong, B.C., Lui, G.C., Sin, W.W., Wong, R.Y., Lam, W.Y., Yeung, A.C., Leung, T.F., So, H.Y., Yu, A.W., Sung, J.J., Hui, D.S., Viral clearance and inflammatory response patterns in adults hospitalized for pandemic 2009 influenza A(H1N1)Virus pneumonia. Antivir. Ther. 16 (2011), 237–247.
80. Lee, N., Chan, P.K., Lui, G.C., Wong, B.C., Sin, W.W., Choi, K.W., Wong, R.Y., Lee, E.L., Yeung, A.C., Ngai, K.L., Chan, M.C., Lai, R.W., Yu, A.W., Hui, D.S., Complications and outcomes of pandemic 2009 influenza a (H1N1) in hospitalized adults – how are they different from seasonal influenza?. J. Infect. Dis. 203 (2011), 1739–1747.
81. Lee, N., Leo, Y.S., Cao, B., Chan, P.K., Kyaw, W.M., Uyeki, T.M., Tam, W.W., Cheung, C.S., Yung, I.M., Li, H., Gu, L., Liu, Y., Liu, Z., Qu, J., Hui, D.S., Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients. Eur. Respir. J. 45 (2015), 1642–1652.
82. Lee, N., Wong, C.K., Chan, M.C., Yeung, E.S., Tam, W.W., Tsang, O.T., Choi, K.W., Chan, P.K., Kwok, A., Lui, G.C., Leung, W.S., Yung, I.M., Wong, R.Y., Cheung, C.S., Hui, D.S., Anti-inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: a randomized controlled trial. Antivir. Res. 144 (2017), 48–56.
83. Lee, S.M., Gai, W.W., Cheung, T.K., Peiris, J.S., Antiviral effect of a selective COX-2 inhibitor on H5N1 infection in vitro. Antivir. Res. 91 (2011), 330–334.
84. Lejal, N., Tarus, B., Bouguyon, E., Chenavas, S., Bertho, N., Delmas, B., Ruigrok, R.W., Di Primo, C., Slama-Schwok, A., Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus. Antimicrob. Agents Chemother. 57 (2013), 2231–2242.
85. Li, C., Zhang, A.J., To, K.K., Lee, A.C., Zhu, H., Wu, H.W., Chan, J.F., Chen, H., Hung, I.F., Li, L., Yuen, K.Y., Avian influenza A H7N9 virus induces severe pneumonia in mice without prior adaptation and responds to a combination of zanamivir and COX-2 inhibitor. PLoS One, 9, 2014, e107966.
86. Li, H., Yang, S.G., Gu, L., Zhang, Y., Yan, X.X., Liang, Z.A., Zhang, W., Jia, H.Y., Chen, W., Liu, M., Yu, K.J., Xue, C.X., Hu, K., Zou, Q., Li, L.J., Cao, B., Wang, C., National influenza A(H1N1)pdm09 clinical investigation group of China. Effect of low-to-moderate-dose corticosteroids on mortality of hospitalized adolescents and adults with influenza A(H1N1)pdm09 viral pneumonia. Influenza. Respir Viruses 11 (2017), 345–354.
87. Li, Y., Xu, J., Shi, W., Chen, C., Shao, Y., Zhu, L., Lu, W., Han, X., Mesenchymal stromal cell treatment prevents H9N2 avian influenza virus-induced acute lung injury in mice. Stem Cell Res. Ther., 7, 2016, 159.
88. Lim, W.S., Brittain, C., Duley, L., Edwards, S., Gordon, S., Montgomery, A., Nguyen-Van-Tam, J., Read, R., Whitham, D., Whynes, D., Woodhead, M., Wootton, D., Blinded randomised controlled trial of low-dose Adjuvant Steroids in Adults admitted to hospital with Pandemic influenza (ASAP): a trial ‘in hibernation’, ready for rapid activation. Health Technol. Assess. 19 (2015), 1–78 vii-viii.
89. Linko, R., Pettilä, V., Ruokonen, E., Varpula, T., Karlsson, S., Tenhunen, J., Reinikainen, M., Saarinen, K., Perttilä, J., Parviainen, I., Ala-Kokko, T., FINNH1N1-Study group. Corticosteroid therapy in intensive care unit patients with PCR-confirmed influenza A(H1N1) infection in Finland. Acta Anaesthesiol. Scand. 55 (2011), 971–979.
90. Liu, Z., Guo, Z., Wang, G., Zhang, D., He, H., Li, G., Liu, Y., Higgins, D., Walsh, A., Shanahan-Prendergast, L., Lu, J., Evaluation of the efficacy and safety of a statin/caffeine combination against H5N1, H3N2 and H1N1 virus infection in BALB/c mice. Eur. J. Pharmaceut. Sci. 38 (2009), 215–223.
91. Louie, J.K., Yang, S., Acosta, M., Yen, C., Samuel, M.C., Schechter, R., Guevara, H., Uyeki, T.M., Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin. Infect. Dis. 55 (2012), 1198–1204.
92. Lu, J., Guo, Z., Pan, X., Wang, G., Zhang, D., Li, Y., Tan, B., Ouyang, L., Yu, X., Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice. Respir. Res., 7, 2006, 43.
93. Luke, T., Kilbane, E., Jackson, J., Hoffman, S., Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?. Ann. Intern. Med. 145 (2006), 599–609.
94. Martin-Loeches, I., Lisboa, T., Rhodes, A., Moreno, R.P., Silva, E., Sprung, C., Chiche, J.D., Barahona, D., Villabon, M., Balasini, C., Pearse, R.M., Matos, R., Rello, J., ESICM H1N1 Registry Contributors. Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection. Intensive Care Med. 37 (2011), 272–283.
95. Martín-Loeches, I., Bermejo-Martin, J.F., Vallés, J., Granada, R., Vidaur, L., Vergara-Serrano, J.C., Martín, M., Figueira, J.C., Sirvent, J.M., Blanquer, J., Suarez, D., Artigas, A., Torres, A., Diaz, E., Rodriguez, A., Semicyuc/REIPI/CIBERES H1N1 working group. Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia. Intensive Care Med. 39 (2013), 693–702.
96. Mata, M., Morcillo, E., Gimeno, C., Cortijo, J., N-acetyl-L-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV). Biochem. Pharmacol. 82 (2011), 548–555.
97. Miyamoto, D., Hasegawa, S., Sriwilaijaroen, N., Yingsakmongkon, S., Hiramatsu, H., Takahashi, T., Hidari, K., Guo, C.T., Sakano, Y., Suzuki, T., Suzuki, Y., Clarithromycin inhibits progeny virus production from human influenza virus-infected host cells. Biol. Pharmaceut. Bull. 31 (2008), 217–222.
98. Min, J.Y., Jang, Y.J., Macrolide therapy in respiratory viral infections. Mediat. Inflamm., 2012, 2012, 649570.
99. Mo, Y., Fisher, D., A review of treatment modalities for Middle East Respiratory Syndrome. J. Antimicrob. Chemother. 71 (2016), 3340–3350.
100. Moes, D.J., Guchelaar, H.J., de Fijter, J.W., Sirolimus and everolimus in kidney transplantation. Drug Discov. Today 20 (2015), 1243–1249.
101. Morrison, T.J., Jackson, M.V., Cunningham, E.K., Kissenpfennig, A., McAuley, D.F., O'Kane, C.M., Krasnodembskaya, A.D., Mesenchymal stromal cells modulate macrophages in clinically relevant lung injury models by extracellular vesicle mitochondrial transfer. Am. J. Respir. Crit. Care Med. 196 (2017), 1275–1286.
102. Murray, J.L., McDonald, N.J., Sheng, J., Shaw, M.W., Hodge, T.W., Rubin, D.H., O'Brien, W.A., Smee, D.F., Inhibition of influenza A virus replication by antagonism of a PI3K-AKT-mTOR pathway member identified by gene-trap insertional mutagenesis. Antivir. Chem. Chemother. 22 (2012), 205–215.
103. Muthuri, S.G., Venkatesan, S., Myles, P.R., et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2 (2014), 395–404.
104. National Heart, Lung, and Blood Institute ARDS Clinical Trials Network, Truwit, J.D., Bernard, G.R., Steingrub, J., Matthay, M.A., Liu, K.D., Albertson, T.E., Brower, R.G., Shanholtz, C., Rock, P., Douglas, I.S., deBoisblanc, B.P., Hough, C.L., Hite, R.D., Thompson, B.T., Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N. Engl. J. Med. 370 (2014), 2191–2200.
105. Onodera, H., Urayama, T., Hirota, K., Maeda, K., Kubota-Koketsu, R., Takahashi, K., Hagiwara, K., Okuno, Y., Ikuta, K., Yunoki, M., Neutralizing activities against seasonal influenza viruses in human intravenous immunoglobulin. Biologics 11 (2017), 23–30.
106. Ooi, E.E., Chew, J.S., Loh, J.P., Chua, R.C., In vitro inhibition of human influenza A virus replication by chloroquine. Virol. J., 3, 2006, 39.
107. Papazian, L., Roch, A., Charles, P.E., Penot-Ragon, C., Perrin, G., Roulier, P., Goutorbe, P., Lefrant, J.Y., Wiramus, S., Jung, B., Perbet, S., Hernu, R., Nau, A., Baldesi, O., Allardet-Servent, J., Baumstarck, K., Jouve, E., Moussa, M., Hraiech, S., Guervilly, C., Forel, J.M., STATIN-VAP study group. Effect of statin therapy on mortality in patients with ventilator-associated pneumonia: a randomized clinical trial. J. Am. Med. Assoc. 310 (2013), 1692–1700.
108. Parnham, M.J., Erakovic Haber, V., Giamarellos-Bourboulis, E.J., Perletti, G., Verleden, G.M., Vos, R., Azithromycin: mechanisms of action and their relevance for clinical applications. Pharmacol Ther. 143 (2014), 225–245.
109. Patel, P., Nadwani, V., Vanchiere, J., Conrad, S.A., Scott, L.K., Use of therapeutic plasma exchange as a rescue therapy in 2009 pH1N1 influenza-An associated respiratory failure and hemodynamic shock. Pediatr. Crit. Care Med. 12 (2011), e87–e89.
110. Paton, N.I., Lee, L., Xu, Y., Ooi, E.E., Cheung, Y.B., Archuleta, S., Wong, G., Wilder-Smith, A., Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. Lancet Infect. Dis. 11 (2011), 677–683.
111. Peiris, J.S., Yu, W.C., Leung, C.W., Cheung, C.Y., Ng, W.F., Nicholls, J.M., Ng, T.K., Chan, K.H., Lai, S.T., Lim, W.L., Yuen, K.Y., Guan, Y., Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 363 (2004), 617–619.
112. Powell, D., Bowler, C., Roberts, T., Garton, M., Matthews, C., McCall, I., Davie, M., Incidence of serious side effects with intravenous bisphosphonate: a clinical audit. QJM 105 (2012), 965–971.
113. Qin, G., Liu, Y., Zheng, J., Xiang, Z., Ng, I.H., Malik Peiris, J.S., Lau, Y.L., Tu, W., Phenotypic and functional characterization of human γδ T-cell subsets in response to influenza A viruses. J. Infect. Dis. 205 (2012), 1646–1653.
114. Radigan, K.A., Urich, D., Misharin, A.V., Chiarella, S.E., Soberanes, S., Gonzalez, A., Perlman, H., Wunderink, R.G., Budinger, G.R., Mutlu, G.M., The effect of rosuvastatin in a murine model of influenza A infection. PLoS One, 7, 2012, e35788.
115. Ray, W.A., Murray, K.T., Hall, K., Arbogast, P.G., Stein, C.M., Azithromycin and the risk of cardiovascular death. N. Engl. J. Med. 366 (2012), 1881–1890.
116. Robbins, C.S., Bauer, C.M., Vujicic, N., Gaschler, G.J., Lichty, B.D., Brown, E.G., Stämpfli, M.R., Cigarette smoke impacts immune inflammatory responses to influenza in mice. Am. J. Respir. Crit. Care Med. 174 (2006), 1342–1351.
117. Rockman, S., Lowther, S., Camuglia, S., Vandenberg, K., Taylor, S., Fabri, L., Miescher, S., Pearse, M., Middleton, D., Kent, S.J., Maher, D., Intravenous immunoglobulin protects against severe pandemic influenza infection. EBio Med. 19 (2017), 119–127.
118. Rodrigo, C., Leonardi-Bee, J., Nguyen-Van-Tam, J., Lim, W.S., Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst. Rev., 3, 2016, CD010406.
119. Ronco, C., Klein, D.J., Polymyxin B hemoperfusion: a mechanistic perspective. Crit. Care, 18, 2014, 309.
120. Rossignol, J.F., La Frazia, S., Chiappa, L., Ciucci, A., Santoro, M.G., Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J. Biol. Chem. 284 (2009), 29798–29808.
121. Rossignol, J.F., Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antivir. Res. 110 (2014), 94–103.
122. Saxton, R.A., Sabatini, D.M., mTOR signaling in growth, metabolism, and disease. Cell 169 (2017), 361–371.
123. Schwab, I., Nimmerjahn, F., Intravenous immunoglobulin therapy: how does IgG modulate the immune system?. Nat. Rev. Immunol. 13 (2013), 176–189.
124. Siris, E.S., Lyles, K.W., Singer, F.R., Meunier, P.J., Medical management of Paget's disease of bone: indications for treatment and review of current therapies. J. Bone Miner. Res. 21:2 (2006), 94–98.
125. Soo, Y.O., Cheng, Y., Wong, R., Hui, D.S., Lee, C.K., Tsang, K.K., Ng, M.H., Chan, P., Cheng, G., Sung, J.J., Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin. Microbiol. Infect. 10 (2004), 676–678.
126. Sun, S., Zhao, G., Liu, C., Fan, W., Zhou, X., Zeng, L., Guo, Y., Kou, Z., Yu, H., Li, J., Wang, R., Li, Y., Schneider, C., Habel, M., Riedemann, N.C., Du, L., Jiang, S., Guo, R., Zhou, Y., Treatment with anti-C5a antibody improves the outcome of H7N9 virus infection in African green monkeys. Clin. Infect. Dis. 60 (2015), 586–595.
127. Takeda, S., Munakata, R., Abe, S., Mii, S., Suzuki, M., Kashiwada, T., Azuma, A., Yamamoto, T., Gemma, A., Tanaka, K., Hypercytokinemia with 2009 pandemic H1N1 (pH1N1) influenza successfully treated with polymyxin B-immobilized fiber column hemoperfusion. Intensive Care Med. 36 (2010), 906–907.
128. Tanvetyanon, T., Stiff, P.J., Management of the adverse effects associated with intravenous bisphosphonates. Ann. Oncol. 17 (2006), 897–907.
129. Tarrant, B.J., Le Maitre, C., Romero, L., Steward, R., Button, B.M., Thompson, B.R., Holland, A.E., Mucoactive agents for chronic, non-cystic fibrosis lung disease: a systematic review and meta-analysis. Respirology 22 (2017), 1084–1092.
130. Tian, X., Jiang, Z., Ma, Q., Liu, Q., Lu, X., Liu, W., Liao, X., Zhou, R., Su, X., Luo, Q., Prevalence of neutralizing antibodies to common respiratory viruses in intravenous immunoglobulin and in healthy donors in southern China. J. Thorac. Dis. 8 (2016), 803–812.
131. To, K.F., Chan, P.K., Chan, K.F., Lee, W.K., Lam, W.Y., Wong, K.F., Tang, N.L., Tsang, D.N., Sung, R.Y., Buckley, T.A., Tam, J.S., Cheng, A.F., Pathology of fatal human infection associated with avian influenza A H5N1 virus. J. Med. Virol. 63 (2001), 242–246.
132. To, K.K., Hung, I.F., Li, I.W., Lee, K.L., Koo, C.K., Yan, W.W., Liu, R., Ho, K.Y., Chu, K.H., Watt, C.L., Luk, W.K., Lai, K.Y., Chow, F.L., Mok, T., Buckley, T., Chan, J.F., Wong, S.S., Zheng, B., Chen, H., Lau, C.C., Tse, H., Cheng, V.C., Chan, K.H., Yuen, K.Y., Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin. Infect. Dis. 50 (2010), 850–859.
133. To, K.K., Mok, K.Y., Chan, A.S., Cheung, N.N., Wang, P., Lui, Y.M., Chan, J.F., Chen, H., Chan, K.H., Kao, R.Y., Yuen, K.Y., Mycophenolic acid, an immunomodulator, has potent and broad-spectrum in vitro antiviral activity against pandemic, seasonal and avian influenza viruses affecting humans. J. Gen. Virol. 97 (2016), 1807–1817.
134. Trombetta, C., Piccirella, S., Perini, D., Kistner, O., Montomoli, E., Emerging influenza strains in the last two decades: a threat of a new pandemic?. Vaccines 3 (2015), 172–185.
135. Tu, W., Zheng, J., Liu, Y., Sia, S.F., Liu, M., Qin, G., Ng, I.H., Xiang, Z., Lam, K.T., Peiris, J.S., Lau, Y.L., The aminobisphosphonate pamidronate controls influenza pathogenesis by expanding a gammadelta T cell population in humanized mice. J. Exp. Med. 208 (2011), 1511–1522.
136. van Griensven, J., Edwards, T., de Lamballerie, X., Semple, M.G., Gallian, P., Baize, S., Horby, P.W., Raoul, H., Magassouba, N., Antierens, A., Lomas, C., Faye, O., Sall, A.A., Fransen, K., Buyze, J., Ravinetto, R., Tiberghien, P., Claeys, Y., De Crop, M., Lynen, L., Bah, E.I., Smith, P.G., Delamou, A., De Weggheleire, A., Haba, N., Ebola-Tx Consortium. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N. Engl. J. Med. 374 (2016), 33–42.
137. Vandermeer, M.L., Thomas, A.R., Kamimoto, L., Reingold, A., Gershman, K., Meek, J., Farley, M.M., Ryan, P., Lynfield, R., Baumbach, J., Schaffner, W., Bennett, N., Zansky, S., Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J. Infect. Dis. 205 (2012), 13–19.
138. Vigerust, D.J., McCullers, J.A., Chloroquine is effective against influenza A virus in vitro but not in vivo. Influenza. Respir Viruses 1 (2007), 189–192.
139. Villarroel, M.C., Hidalgo, M., Jimeno, A., Mycophenolate mofetil: an update. Drugs Today 45 (2009), 521–532.
140. Volkmann, E.R., Tashkin, D.P., Li, N., Roth, M.D., Khanna, D., Hoffmann-Vold, A.M., Kim, G., Goldin, J., Clements, P.J., Furst, D.E., Elashoff, R.M., Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of scleroderma lung studies I and II. Arthritis Rheumatol. 69 (2017), 1451–1460.
141. Waljee, A.K., Rogers, M.A., Lin, P., Singal, A.G., Stein, J.D., Marks, R.M., Ayanian, J.Z., Nallamothu, B.K., Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ, 357, 2017, j1415.
142. Wang, C., Cao, B., Liu, Q.Q., Zou, Z.Q., Liang, Z.A., Gu, L., Dong, J.P., Liang, L.R., Li, X.W., Hu, K., He, X.S., Sun, Y.H., An, Y., Yang, T., Cao, Z.X., Guo, Y.M., Wen, X.M., Wang, Y.G., Liu, Y.L., Jiang, L.D., Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial. Ann. Intern. Med. 155 (2011), 217–225.
143. Wang, C.H., Chung, F.T., Lin, S.M., Huang, S.Y., Chou, C.L., Lee, K.Y., Lin, T.Y., Kuo, H.P., Adjuvant treatment with a mammalian target of rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe H1N1 pneumonia and acute respiratory failure. Crit. Care Med. 42 (2014), 313–321.
144. Wei, S.H., Yang, J.R., Wu, H.S., Chang, M.C., Lin, J.S., Lin, C.Y., Liu, Y.L., Lo, Y.C., Yang, C.H., Chuang, J.H., Lin, M.C., Chung, W.C., Liao, C.H., Lee, M.S., Huang, W.T., Chen, P.J., Liu, M.T., Chang, F.Y., Human infection with avian influenza A H6N1 virus: an epidemiological analysis. Lancet Respir Med. 1 (2013), 771–778.
145. Weitz-Schmidt, G., Welzenbach, K., Brinkmann, V., Kamata, T., Kallen, J., Bruns, C., Cottens, S., Takada, Y., Hommel, U., Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. 7 (2001), 687–692.
146. Wen, Y.C., Hsiao, F.Y., Chan, K.A., Lin, Z.F., Shen, L.J., Fang, C.C., Acute respiratory infection and use of nonsteroidal anti-inflammatory drugs on risk of acute myocardial infarction: a nationwide case-crossover study. J. Infect. Dis. 215 (2017), 503–509.
147. World Health Organization, WHO Guidelines for Pharmacological Management of Pandemic (H1N1) 2009 Influenza and Other Influenza Viruses. 2010 Available at: http://www.who.int/csr/resources/publications/swineflu/h1n1_use_antivirals_20090820/en/. (Accessed 13 December 2017)
148. World Health Organization, Influenza (Seasonal) Fact Sheet. 2016 Available at: http://www.who.int/mediacentre/factsheets/fs211/en/. (Accessed 23 October 2017)
149. Wu, X.X., Gao, H.N., Wu, H.B., Peng, X.M., Ou, H.L., Li, L.J., Successful treatment of avian-origin influenza A (H7N9) infection using convalescent plasma. Int. J. Infect. Dis. 41 (2015), 3–5.
150. Yamaya, M., Shinya, K., Hatachi, Y., Kubo, H., Asada, M., Yasuda, H., Nishimura, H., Nagatomi, R., Clarithromycin inhibits type a seasonal influenza virus infection in human airway epithelial cells. J. Pharmacol. Exp. Ther. 333 (2010), 81–90.
151. Yan, Y., Zou, Z., Sun, Y., Li, X., Xu, K.F., Wei, Y., Jin, N., Jiang, C., Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res. 23 (2013), 300–302.
152. Young, P., Saxena, M., Bellomo, R., Freebairn, R., Hammond, N., van Haren, F., Holliday, M., Henderson, S., Mackle, D., McArthur, C., McGuinness, S., Myburgh, J., Weatherall, M., Webb, S., Beasley, R., HEAT investigators; Australian and New Zealand intensive care society clinical trials group. Acetaminophen for fever in critically ill patients with suspected infection. N. Engl. J. Med. 373 (2015), 2215–2224.
153. Zarogoulidis, P., Papanas, N., Kioumis, I., Chatzaki, E., Maltezos, E., Zarogoulidis, K., Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur. J. Clin. Pharmacol. 68 (2012), 479–503.
154. Zhang, R.H., Li, C.H., Wang, C.L., Xu, M.J., Xu, T., Wei, D., Liu, B.J., Wang, G.H., Tian, S.F., N-acetyl-l-cystine (NAC) protects against H9N2 swine influenza virus-induced acute lung injury. Int Immunopharmacol 22 (2014), 1–8.
155. Zheng, B.J., Chan, K.W., Lin, Y.P., Zhao, G.Y., Chan, C., Zhang, H.J., Chen, H.L., Wong, S.S., Lau, S.K., Woo, P.C., Chan, K.H., Jin, D.Y., Yuen, K.Y., Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci U S A 105 (2008), 8091–8096.
156. Zheng, J., Wu, W.L., Liu, Y., Xiang, Z., Liu, M., Chan, K.H., Lau, S.Y., Lam, K.T., To, K.K., Chan, J.F., Li, L., Chen, H., Lau, Y.L., Yuen, K.Y., Tu, W., The therapeutic effect of pamidronate on lethal avian influenza a H7N9 virus infected humanized mice. PLoS One, 10, 2015, e0135999.
157. Zhou, B., Zhong, N., Guan, Y., Treatment with convalescent plasma for influenza A (H5N1) infection. N. Engl. J. Med. 357 (2007), 1450–1451.
158. Zhou, J., Wang, D., Gao, R., Zhao, B., Song, J., Qi, X., Zhang, Y., Shi, Y., Yang, L., Zhu, W., Bai, T., Qin, K., Lan, Y., Zou, S., Guo, J., Dong, J., Dong, L., Zhang, Y., Wei, H., Li, X., Lu, J., Liu, L., Zhao, X., Li, X., Huang, W., Wen, L., Bo, H., Xin, L., Chen, Y., Xu, C., Pei, Y., Yang, Y., Zhang, X., Wang, S., Feng, Z., Han, J., Yang, W., Gao, G.F., Wu, G., Li, D., Wang, Y., Shu, Y., Biological features of novel avian influenza A (H7N9) virus. Nature 499 (2013), 500–503.